Margarita L. Dubocovich PhD, FACNP, FASPET
Margarita L. Dubocovich
PhD, FACNP, FASPET
SUNY Distinguished Professor
Department of Pharmacology and Toxicology
Jacobs School of Medicine & Biomedical Sciences
Specialty/Research Focus
Behavioral pharmacology; Circadian Rhythm/Chronobiology; Drug Design; Drug Targeting; Neuropharmacology; Signal Transduction
Professional Summary:
Neuropharmacology and Neuroscience Research: My team’s work on neuropharmacology and neuroscience focuses on translational research, specifically on drug discovery and development of ligands for melatonin receptors which are targets for therapeutic interventions. The goal of our research is to understand the biology and pharmacology of the molecule melatonin and its receptors, and to identify ligands to be used as research tools or with therapeutic potential. Molecular based drug design, computer modeling, and medicinal chemistry approaches guides the design and synthesis of small molecules targeting MT1 and/or MT2 melatonin receptors as potential treatments for insomnia, circadian sleep disorders, depression, seasonal affective disorders, cardiovascular disease, and cancer (1, 2).
Our laboratory pursues these investigations from a multitude of approaches. We determine the localization of the melatonin receptors, examine their cellular and molecular signaling mechanisms, and investigate receptor fate following prolonged exposure to melatonin. We study the role of melatonin receptors in modulating methamphetamine induce sensitization, reward, and the entrainment of disrupted circadian rhythms. We have also engaged in identifying environmental melatonin circadian disruptors targeting (e.g., carbamate insecticides) the MT1 and/or MT2 melatonin receptors (3). We also study cell proliferation, survival, and neurogenesis in the brain, and the changes in gene expression underlying all these processes. In clinical studies we have demonstrated melatonin effectiveness in advancing circadian phase in subjects with Delayed Sleep Phase Syndrome.
Translational Research Experience: I have experience in drug discovery and development research acquired while employed at pharmaceutical companies (Wellcome Labs; Synthelabo now Sanofi-Aventis), in academic settings while collaborating directly with Nelson Research (1985-1989), Glaxo Welcome (1990-1995), Takeda Pharmaceutical North America (2005-2008) and at academic Institutions. Throughout these collaborations and partnerships, I contributed to the discovery and development of melatonin ligands and established screening programs at the companies I collaborated with, and at my home institutions (1,2). At University at Buffalo, I have leadership roles within the Clinical and Translational Science Institute (CTSI). As Director of the CTSA Translational Workforce Development Core (2015 to 2022) together with my team we developed professional development and grant writing workshops, the Community of Scholars Distinguished Seminar Series. and over 290 workshops grouped in fourteen distinct core competencies in clinical and translational research workshop series. I am currently the PI and Lead for the CTSA-linked KL2 Mentor Career Development Award, and the Director of CTSI K Scholars Program (2020-present) with focus on the recruitment, training and mentoring junior faculty engaged in clinical translation research. Taken together we have developed a focus curriculum for our K Scholars to provide research mentoring, career, and professional development to twenty-two scholars who are successfully navigating their path to independence as reflected by their solid portfolio of academic and research accomplishments. Together, our mentoring programs have developed unique mentoring programs to train the next generation of scientists in clinical and translational science.
Research Mentoring and Educational Leadership. I am an enthusiastic advocate for the training and development of communities of scientists including undergraduates and graduate students to postdoctoral fellows and junior faculty, interested in careers in biomedical, behavioral and STEM science bringing various prospectives to accelerate discovery, and to increase educational outcomes, innovation, and productivity. I have served as direct research mentor in my research team to 49 master’s, PhD students and postdoctoral fellows and over 30 junior faculty. In addition, during my tenure as CLIMB Director at both at Northwestern University and University at Buffalo (2007-2022), our mentoring programs for undergraduates, graduate and postdoctoral fellows/junior faculty impacted the careers of 681 scholars, 445 women in STEM (65% of participants) and 321 Underserved Groups in STEM (47% of participants).
I am currently the PI and Director of the NIH (NIGMS) funded T32-Initiative for Maximizing Students Development (2012-present), PI and Lead of the NIH (NCATS) funded CTSA-linked for the KL2 Mentor Career Development Award (2015-present), Director of the CTSI K Scholars program (2016-present), and Director of the Summer Undergraduate Research Fellowship (SURF) funded by the American Society for Pharmacology and Experimental Therapeutics (ASPET) (2010-present). In summary, I have been contributing to and developing the next generation of 21st century leaders in STEM, health, and clinical and translational science, by offering comprehensive professional development and educational programs.
Administrative Experience. My administrative experience includes being former Chair of the Department of Pharmacology and Toxicology (2008-2016), Senior Associate Dean of Inclusion and Cultural Enhancement (2012-2022), and Founder and Director of the Collaborative Learning and Integrated Mentoring in the Bioscience (CLIMB) Program at UB (2009-2022). Further, I directed the Initiative for Maximizing Student Development (IMSD) award (R25-NIGMS, NIH) at Northwestern University for two years (2007-2008) and at UB since the R25-NIGMS (NIH) was awarded (2012- 2021) and renewed in 2022 as a T32. I co-directed the UB Institute for Strategic Enhancement of Educational Diversity (iSEED) (2013-2022) that we founded in 2013 to promote and bring together initiatives to build inclusive communities of scholars at UB.
Citations
1. Liu J, Clough SJ, Hutchinson AJ, Adamah-Biassi EB, Popovska-Gorevski M, Dubocovich ML. 2016. MT1 and MT2 melatonin receptors: A therapeutic perspective. Annu. Rev. Pharmacol. Toxicol. 56:8.1–8.23. PMC 5091650.
2. Stein RM, Kang HJ, McCorvy JD, Glatfelter GC, Jones AJ, Che T, Slocum S, Huang X-P, Savych O, Moroz YS, Stauch B, Johansson LC, Cherezov V, Kenakin T, Irwin JJ, Shoichet BK, Roth BL, Dubocovich ML. 2020. Virtual discovery of melatonin receptor selective ligands to modulate circadian rhythms. Nature 579:609-633 (published on line 02-10-2020; DOI 1038/s41586-020-2027-0).
3. Glatfelter, G., Jones, A. J., Rajnarayanan, R. V., and Dubocovich, M. L. 2021. Pharmacological Actions of Carbamate Insecticides in Mammalian Melatonin Receptors. J Pharmacol Exp Ther 376:306–321.
Education and Training:
- PhD, Pharmacology, University of Buenos Aires School of Chemistry and Natural Sciences (1976)
- BS, Biological Chemistry, University of Buenos Aires School of Chemistry and Natural Sciences (1971)
Employment:
- Program Lead CTSI K Scholars program, Clinical and Translational Science Institute (CTSI), University at Buffalo (2020-present)
- SUNY Distinguished Professor at University at Buffalo, SUNY, University at Buffalo, Buffalo NY Jacobs School of Medicine and Biomedical Sciences Sciences State University of New York (SUNY),NY (2014-present)
- Professor Emerita at Northwestern University, Pharmacology, Northwestern University Northwestern University Feinberg School of Medicine, Chicago, IL (2008-present)
- PI and Director T32-Initiative for Maximizing Student Development, Jacobs School, SOM, SPHHP, SPPS, CAS, SEAS, RoswellPark, University at Buffalo (2012-present)
- PI and Program Lead, KL2 Mentored Career Development Award, Clinical and Translational Science Institute (CTSI), University at Buffalo (2015–2025)
- PI and Director ASPET SURF Summer program, Jacobs School, SPPS, University at Buffalo (2010–2024)
- Director and Founder, CLIMB Pathways at University at Buffalo, University at Buffalo, University at Buffalo (2017–2022)
- Director, Workforce Development Core (CTSA), Clinical & Translational Science Institute (CTSI),, University at Buffalo (2015–2022)
- Co-Director/Co-Founder, Institute for Strategic Enhancement of Educational Diversity (iSEED)), University at Buffalo, University at Buffalo (2013–2022)
- Senior Associate Dean for Diversity and inclusion (2016-2022); Inaugural Senior Associate Dean for Inclusion and Cultural Enhancement (2012-2016), School of Medicine and Biomedical Sciences, University at Buffalo (2012–2022)
- Director and Founder, CLIMB NS at University at Buffalo, University at Buffalo, University at Buffalo (2010–2022)
- Director and Founder, CLIMB HI Program at University at Buffalo, University at Buffalo, University at Buffalo (2009–2022)
- Director and Founder, CLIMB Program at University at Buffalo, University at Buffalo, University at Buffalo (2009–2022)
- Director and Founder, CLIMB UP Program at University at Buffalo, University at Buffalo, University at Buffalo (2009–2022)
- Department Chair at University at Buffalo, Pharmacology and Toxicology, University at Buffalo Jacobs School of Medicine and Biomedical Sciences (2008–2016)
- Director, Education and Diversity at University at Buffalo NSF Science and Technology Cen, BioXFEL, Science and Technology Center, NSF Science and Technology Center (STC) at University at Buffalo . (2013–2014)
- Professor at University at Buffalo, Pharmacology and Toxicology, University at Buffalo Jacobs School of Medicine and Biomedical Sciences (2008–2014)
- Director and Founder, The Collaborative Learning and Integrated Mentoring in the Biosciences (CLIMB) Program Director, Northwestern University, Northwestern University, Chicago-Evanston, IL (2007–2008)
- Professor at Northwestern UNiversity, Molecular Pharmacology and Biological Chemistry, Northwestern University Feinberg School of Medicine (1991–2008)
- Associate Professor at Northwestern University, Pharmacology, Northwestern University Feinberg School of Medicine (1986–1990)
- Assistant Professor at Northwestern University, Pharmacology, Northwestern University Feinberg School of Medicine (1982–1986)
- Project Leader, Synthelabo - France (1977–1980)
- Pharmacologist, Wellcome Research Laboratories-England (1976–1977)
- Instructor, Pharmacology, Buenos Aires University School of Medicine (1973–1976)
- Instructor, Biochemistry, Buenos Aires University School of Chemistry and Natural Sciences (1971–1972)
- Teaching Assistant, Organic Chemistry, Buenos Aires University School of Chemistry and Natural Sciences (1970–1971)
Awards and Honors:
- 2025 U.S.A. President Award of Excellence in Science, Mathematics and Engineering Mentoring (PAESMEM) by the White House and the National Science Foundation (Recognition: TBD) (2025)
- 2024 Association of Clinical and Translational Science (ACTS) Award for Contributions to Diversity and Inclusiveness to the Translational Workforce. (2024)
- 2022 Julius Axelrod Award in Pharmacology (2022)
- 2021 Scientific Achievement Award: Norman Weiner Memorial Lecture from the American Society of Pharmacology and Experimental Therapeutics (2021)
- 2020 Inaugural Buffalo Bussines First Inclusion, Diversity, Equity, Awarness (IDEA) Award (2020)
- 2020 Fellow of the American Society of Pharmacology and Experimental Therapeutics (FASPET) (2020)
- 2020 Inspiring Programs in STEM Award (2020)
- 2017 Inaugural ACNP Delores C Shockley Minority Mentoring Award (2017)
- 2017 UB CSTEP Outstanding Research Mentor Award (2017)
- 2017 UB President’s Medal (2017)
- 2015 Excellence in Graduate Student Mentoring Award (2015)
- 2014 SUNY Distinguished Academy Member (2014)
- 2013 School of Medicine and Biomedical Sciences Dean's Award (2013)
- 2013 Fellow of the American College of Neuropsychopharmacology (FACNP). (2013)
- 2012 Foundation Award in Excellence in Pharmacology/Toxicology (2012)
- 2011 Mayor Byron W Brown Hispanic Heritage Recognition Award (2011)
- 2011 Aaron B Lerner Award for Outstanding Contributions to Melatonin Research (2011)
- 2011 Distinguished Postdoctoral Mentor Award (2011)
- 2005 Outstanding Scientific Contributions Award (2005)
- 1999 Visiting Scientist for Minority Institutions (1999)
- 1989 American Physiological Society Travel Award (1989)
- 1983 PhRMA Foundation Starter Research Grant Award (1983)
- 1981- Travel Awards to attend IUPHAR Congresses (1981-1984-1987-1990-1998) (1981)
- 1974 Advance Research Fellow - National Research Council of Argentina (1974)
- 1971 Research Fellow - National Research Council of Argentina (1971)
Research Expertise:
- Circadian Rhythms: Melatonin (MT1 and MT2) receptors as targets for the modulation of circadian rhythms
- Drug Discovery: Discovery of receptor-selective melatonin ligands for the treatment of circadian sleep disorders, depression, and cancer
- Metabolism: Metabolism, methamphetamine-induced sensitization, cell proliferation neurogenesis
- Neuropharmacology: Cellular, molecular and behavioral neuropharmacology of G protein-coupled receptors
Research Centers:
- Clinical and Translational Research Center (CTRC)
- Toxicology Research Center (TRC)
Grants and Sponsored Research:
- August 2020–December 2025
Clinical and Translational Science Award-linked KL2 Mentored Career Development Award
NIH/NCATS
Role: Principal Investigator
$2,706,260 - August 2015–December 2024
Clinical and Translational Science Award: Buffalo Clinical and Translational Research Center
National Center for Advancing Translational Sciences
Role: Co-Investigator
$19,936,155 - May 2020–April 2022
Sustained release of luzindole
UB-Blue Sky Program
Role: Principal Investigator
$10,000 - March 2012–January 2022
Initiative for Maximizing Student Development (IMSD): Enabling Access To Cutting-Edge Biomedical And Behavioral Science
NIH
Role: Principal Investigator
$4,943,038 - January 2021–December 2021
A pilot placebo-controlled randomized double-blind trial of Melatonin in outpatients with COVID-19 infection
CTSA – Pilot Grant
Role: Principal Investigator
$42,700 - June 2013–June 2021
iSEED – Institute of Strategic Enhancement of Educational Diversity
UB Office of the Provost-3E Fund
Role: Co-Principal Investigator
$1,850,000 - October 2020–December 2020
Research Seed Grant Program
SUNY SEED
Role: Principal Investigator
$7,500 - January 2016–January 2019
Clinical Translational Science Award (CTSA)
National Institutes of Health
Role: Principal Investigator
$16,000,000 - April 2017–December 2018
Discovery of Circadian Modulators Selectively Targeting Melatonin Receptors
Role: Principal Investigator
$40,000 - October 2013–September 2018
National Science Foundation – Science and Technology Center (STC) Biology with X-ray Free Electron Lasers (BioXFEL)
National Science Foundation
Role: Co-Investigator
$25,000,000 - July 2014–June 2018
Environmental Circadian Disruptors Increase Diabetes and Metabolic Disorders Risk
National Institutes of Health
Role: Principal Investigator
$435,355 - June 2010–June 2018
Zannoni Summer Undergraduate Research Fellowship Award
American Society for Pharmacology and Experimental Therapeutics
Role: Principal Investigator
$27,000 - January 2017–December 2017
Professional Pathways
Graduate School - Professional Pathways Planning Grants
Role: Co-Principal Investigator - July 2016–June 2017
Dialogues on Cultural Diversity & Culturally Responsive Health Care
SUNY
Role: Principal Investigator - July 2016–June 2017
SUNY Explorations in Diversity and Academic Excellence Award
SUNY
Role: Principal Investigator
$10,000 - August 2016–December 2016
UB Network for Enriched Academic Relationships
UB-NEAR
Role: Co-Investigator
$10,000 - July 2007–September 2013
Modulation of Methamphetamine Action in the CNS
NIH/NIDA
Role: Principal Investigator
$1,146,760 - April 2009–March 2012
Discovery of Selective MT1 Melatonin Receptor Ligands for Sleep Disorders
NIH/NINDS
Role: Principal Investigator - March 2007–February 2012
Mentoring For Success: Developing Fundamental Skills For Biomedical Research
IMSD: Initiative for Maximizing Student Diversity - April 2004–March 2011
Modulatory Role of Melatonin in CNS Function
NIH/NIMH
Role: Principal Investigator
$1,000,000 - October 2004–September 2009
Alliance Graduate Education and the Professoriate
NSF - June 2005–May 2009
IMSD-Stimulated Institutional Transformation Towards Increasing Student Diversity
IMSD – Administrative Supplement - February 2006–February 2009
Chicago State-Northwestern MS-PhD Bridge to the Future.
Role: Principal Investigator - December 2001–November 2008
Melatonin Receptors as Therapeutic Targets in Primates
NIH/NIMH
Role: Principal Investigator
$1,125,000 - August 2006–August 2008
Regulation of MT1 and MT2 Melatonin Receptor Functional Sensitivity By Therapeutic Concentrations Of Rozerem.
Takeda
Role: Principal Investigator - September 2002–September 2004
“Melatonin Regulation of MT2 Melatonin Receptors.”
NRSA - February 1997–February 2002
“Sleep/Wake Rhythms in Aging: Treatment with Nimodipine.” - April 2000–June 2001
“Melatonin receptors: Characterization of binding domains.”
NRSA - January 2000–December 2000
“Strategies for Developing a Screening Test for MT3 melatonin Receptor Mediated Functional Activity”
Servier
Role: Principal Investigator - January 1998–December 1999
“Melatonin Receptor Subtypes in Mammalian Vascular Vessels.”
Grant-In-Aid AHAMC - AHA/AHAMC. - May 1996–April 1999
“Melatonin-Light Interaction on Circadian Activity.”
Role: Principal Investigator - February 1996–February 1999
“Melatonin-Light Interaction in Circadian Activity.” - January 1997–January 1998
“Novel Melatonin Analogues: Assessment of Affinity Constants.”
Eli Lilly and Company - October 1995–September 1996
“Structure/Function Relationships and Regulation of the Human ML1 Melatonin Receptor.” - May 1992–April 1996
“Modulatory Role of Melatonin in CNS Function.”
USPHS R01
Role: Principal Investigator - December 1991–November 1995
“Neural Substrates of Learning Deficit due to PCP Abuse.”
USPHS R01
Role: Co-Investigator - September 1993–August 1995
“Melatonin and Aging.” - July 1990–June 1995
“Pharmacology of Pineal Gland Biochemical Mediators”
Glaxo, Inc. - August 1990–December 1991
“Melatonin Neurotransmitter Interactions.” - April 1987–March 1991
“Characterization of Melatonin Receptors in Brain.”
Role: Principal Investigator - September 1987–June 1990
“Modulatory Role of Melatonin in CNS Function.”
USPHS R01
Role: Principal Investigator - April 1989–March 1990
“Melatonin Neurotransmitter Interactions.”
Biomedical Research Support (NUDS)
Role: Principal Investigator - April 1987–December 1988
“In Search for Melatonin Receptor Antagonists.”
Nelson Research
Role: Principal Investigator - October 1985–September 1987
“Melatonin Receptors in Hamster Brain.” - April 1985–March 1987
“Screening Melatonin Agonists and Antagonists.”
Nelson Research - February 1986–January 1987
Noradrenergic Modulation of Serotonergic Activity
Biomedical Research Support (NUMS)
Role: Principal Investigator - July 1985–December 1986
“Studies on Cyclohexylamine.”
Nutrasweet Corporation - January 1985–December 1986
“Regulation by Melatonin of Monoamine Receptors in Endogenous Depression.”
NSF, United States Spain Cooperative Program in Basic Sciences US Spain
Role: Principal Investigator - October 1984–September 1986
“Autoreceptor Sensitivity After Antidepressant Treatment.” - September 1983–August 1986
“Dopamine receptor subtypes in vascular tissues.”
American Heart Association (with funds contributed by Chicago Heart Association)
Role: Principal Investigator - April 1985–March 1986
“Mechanisms of Pyrethroid Insecticide Action.”
Biomedical Research Support (NUMS)
Role: Principal Investigator - April 1983–March 1986
“Characterization of Retinal Dopamine Receptors"
USPHS R01
Role: Principal Investigator - April 1984–March 1985
“Alpha and Dopamine Receptor Sensitivity After Antidepressant Treatment.”
Biomedical Research Support (NUMS)
Role: Principal Investigator - January 1983–December 1983
“Role of calcium and cyclic nucleotides on the modulation of depolarization induced release of 3H dopamine from the rabbit retina in vitro.”
Pharmaceutical Manufacturers Association Foundation Starter Grant
Role: Principal Investigator
Patents:
- “Modulators Of Circadian Rhythms And Uses There of”. SCHOICET, B.K., DUBOCOVICH, M.L., et al. (International Patent Application No. PCT/US20/48233): “Modulators Of Circadian Rhythms And Uses There of”. U.S. Patent and Trademark Office. Filing date: August 27, 2020; Applicants: The Research Foundation of the University at Buffalo University of Buffalo , The Reagents of the University of California San Francisco, and University of North Carolina at Chapel Hill. (Pending). (2020)
- “Modulators Of Circadian Rhythms And Uses Thereof." SCHOICET, B.K., DUBOCOVICH, M.L., et al. (U.S. Patent Application No. 62/893,115): “Modulators Of Circadian Rhythms And Uses Thereof. U.S. Patent and Trademark Office. Filing date: August 28, 2019; Applicants: The Research Foundation of the University at Buffalo University of Buffalo , The Reagents of the University of California San Francisco, and University of North Carolina at Chapel Hill. (Pending). (2019)
- Pharmaceutical Combination For Mood Disorders. BENITEZ KING, G.A., DORANTES BARRÓN, A.M., DUBOCOVICH, M.L., ESTRADA REYES, R., QUERO CHÁVEZ, B.D., TRUETA SEGOVIA, C. (International Patent Application No. Mx/a/2018/002510). Pharmaceutical Combination For Mood Disorders. Filing date: March 2018. Applicants: University of Buffalo, Buffalo, NY; Instituto Nacional De Psiquiatría "Ramón De La Fuente Muñíz, Mexico City, Mexico. (Pending). (2018)
- Pharmaceutical Combination For Mood Disorders. BENITEZ KING, G.A., DORANTES BARRÓN, A.M., DUBOCOVICH, M.L., ESTRADA REYES, R., QUERO CHÁVEZ, B.D., TRUETA SEGOVIA, C. (Mexico. Patent Application No. MX2015014385). “Combinación Farmacéutica Para Trastornos Del Estado De Ánimo” Pharmaceutical Combination For Mood Disorders. Filing date: October, 2017; Applicants: University of Buffalo, Buffalo, NY; Instituto Nacional De Psiquiatría Ramón De La Fuente Muñíz, Mexico City, Mexico. (2017)
- “2-Aryl Substituted N-Acetyltryptamines and Process of Preparing Such.” DUBOCOVICH, M.L., RAJADHYAKSHA, V.J., PECK, J.V., and HELMY, A.A. (US Patent #5,283,343): “2-Aryl Substituted N-Acetyltryptamines and Process of Preparing Such.” U.S. Patent and Trademark Office, filed 8/17/87. Issued: February 1994. (1994)
- “2 Amidotetralines as Melatonin Agonists and antagonists.” HORN, A.S. and DUBOCOVICH, M.L. (US Patent # 5,151,446): “2 Amidotetralines as Melatonin Agonists and antagonists.” U.S. Patent and Trademark Office, filed 9/26/89. Issued: September 29, 1992. (1992)
- “Antidepressants Agents.” DUBOCOVICH, M.L. (US Patent # 5,093,352): “Antidepressants Agents.” U.S. Patent and Trademark Office, filed 8/17/87. Issued: March 3, 1992. (1992)
Journal Articles:
- Estrada-Reyes R, Quero-Chávez DB, Alarcón-Elizalde S, Cercós MG, Trueta C, Constantino-Jonapa LA, Oikawa-Sala J, Argueta J, Cruz-Garduño R, Dubocovich ML, Benítez-King GA. (2022) Antidepressant Low Doses of Ketamine and Melatonin in Combination Produce Additive Neurogenesis in Human Olfactory Neuronal Precursors. Molecules (Basel, Switzerland) (Sep), 27(17). doi:10.3390/molecules27175650
- Sumaya IC, Dubocovich ML. (2022) Melatonin-mediated attenuation of fluphenazine-induced hypokinesia in C57BL/6 mice is dependent on the light/dark phase. Behavioural brain research (May), 425: 113827.
- Glatfelter GC, Sosa J, Hudson RL, Dubocovich ML. (2022) Methods to Assess Melatonin Receptor-Mediated Phase-Shift and Re-entrainment of Rhythmic Behaviors in Mouse Models. Methods in molecular biology (Clifton, N.J.) (Jan), 2550: 391-411. doi:10.1007/978-1-0716-2593-4_39
- Zhang C, Clough SJ, Adamah-Biassi EB, Sveinsson MH, Hutchinson AJ, Miura I, Furuse T, Wakana S, Matsumoto YK, Okanoya K, Hudson RL, Kato T, Dubocovich ML, Kasahara T. (2021) Impact of endogenous melatonin on rhythmic behaviors, reproduction, and survival revealed in melatonin-proficient C57BL/6J congenic mice. Journal of pineal research (Sep), 71(2): e12748.
- Reynolds JL, Dubocovich ML. (2021) Melatonin multifaceted pharmacological actions on melatonin receptors converging to abrogate COVID-19. Journal of pineal research (Aug), 71(1): e12732. doi:10.1111/jpi.12732
- Estrada-Reyes R, Quero-Chávez DB, Trueta C, Miranda A, Valdés-Tovar M, Alarcón-Elizalde S, Oikawa-Sala J, Argueta J, Constantino-Jonapa LA, Muñoz-Estrada J, Dubocovich ML, Benítez-King G. (2021) Low Doses of Ketamine and Melatonin in Combination Produce Additive Antidepressant-like Effects in Mice. International journal of molecular sciences (Aug), 22(17). doi:10.3390/ijms22179225
- Glatfelter GC, Jones AJ, Rajnarayanan RV, Dubocovich ML. (2021) Pharmacological Actions of Carbamate Insecticides at Mammalian Melatonin Receptors. The Journal of pharmacology and experimental therapeutics (Feb), 376(2): 306-321. doi:10.1124/jpet.120.000065
- Stein RM, Kang HJ, McCorvy JD, Glatfelter GC, Jones AJ, Che T, Slocum S, Huang XP, Savych O, Moroz YS, Stauch B, Johansson LC, Cherezov V, Kenakin T, Irwin JJ, Shoichet BK, Roth BL, Dubocovich ML. (2020) Virtual discovery of melatonin receptor ligands to modulate circadian rhythms. Nature (Jan), 579(7800): 609-614.
- Estrada-Reyes R, Valdés-Tovar M, Arrieta-Baez D, Dorantes-Barrón AM, Quero-Chávez D, SolÃs-Chagoyán H, Argueta J, Dubocovich ML, BenÃtez-King G. (2018) The Timing of Melatonin Administration Is Crucial for Its Antidepressant-Like Effect in Mice. Int J Mol Sci (Aug), 19(8).
- Murphy SL, Samuels EM, Kolb HR, Behar-Horenstein LS, Champagne E, Byks-Jazayeri C, Hahn J, Roth MT, Ennever F, Bajwa W, Singh M, Homish GG, Dubocovich ML. (2018) Best Practices in Social and Behavioral Research: A multisite pilot evaluation of the good clinical practice online training course. J Clin Transl Sci (Apr), 2(2): 95-102.
- Valdés-Tovar M, Estrada-Reyes R, SolÃs-Chagoyán H, Argueta J, Dorantes-Barrón AM, Quero-Chávez D, Cruz-Garduño R, Cercós MG, Trueta C, Oikawa-Sala J, Dubocovich ML, BenÃtez-King G. (2018) Circadian modulation of neuroplasticity by melatonin: a target in the treatment of depression. Br J Pharmacol (Jan), 175(16): 3200-3208.
- Clough SJ, Hudson RL, Dubocovich ML. (2018) Food-induced reinforcement is abrogated by the genetic deletion of the MT1 or MT2 melatonin receptor in C3H/HeN mice. Behav Brain Res (Jan), 343: 28-35.
- Popovska-Gorevski M, Dubocovich ML, Rajnarayanan RV, Rajnarayanan R. (2017) Carbamate Insecticides Target Human Melatonin Receptors. Chem Res Toxicol (Feb), 30(2): 574-582.
- Rawashdeh O, Clough SJ, Hudson RL, Dubocovich ML. (2017) Learned motivation drives circadian physiology in the absence of the master circadian clock. FASEB J (Jan), 31(1): 388-399.
- Liu J, Clough SJ, Dubocovich ML. (2017) Role of the MT1 and MT2 melatonin receptors in mediating depressive- and anxiety-like behaviors in C3H/HeN mice. Genes Brain Behav (Jan), 16(5): 546-553.
- Evely KM, Hudson RL, Dubocovich ML, Haj-Dahmane S. (2016) Melatonin receptor activation increases glutamatergic synaptic transmission in the rat medial lateral habenula. Synapse (May), 70(5): 181-186.
- Jockers R, Delagrange P, Dubocovich ML, Markus RP, Renault N, Tosini G, Cecon E, Zlotos DP. (2016) Update on melatonin receptors: IUPHAR Review 20. Br J Pharmacol (Jan), 173(18): 2702-2725.
- Liu J, Clough SJ, Hutchinson AJ, Adamah-Biassi EB, Popovska-Gorevski M, Dubocovich ML. (2015) MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective. Annu Rev Pharmacol Toxicol (Oct).
- Adamah-Biassi EB, Hudson RL, Dubocovich ML. (2014) Genetic deletion of MT1 melatonin receptors alters spontaneous behavioral rhythms in male and female C57BL/6 mice. Horm Behav (Sep), 66(4): 619-627.
- Clough SJ, Hutchinson AJ, Hudson RL, Dubocovich ML. (2014) Genetic deletion of the MT1 or MT2 melatonin receptors abrogates methamphetamine-induced reward in C3H/HeN mice. Physiol Behav (May).
- Rawashdeh O, Dubocovich ML. (2014) Long-term effects of maternal separation on the responsiveness of the circadian system to melatonin in the diurnal nonhuman primate (Macaca mulatta). J Pineal Res (Apr), 56(3): 254-263.
- Adamah-Biassi, E.B., Zhang Y., Jung H., Vissapragada, S., Miller, R.J., Dubocovich, M.L. (2014) Distribution of MT1 melatonin receptor promoter-driven RFP expression in the brains of BAC C3H/HeN transgenic mice. J Histochemistry and Cytology (Jan), 62(1): 70-84.
- Hutchinson AJ, Ma J, Liu J, Hudson RL, Dubocovich ML. (2014) Role of MT1 melatonin receptors in methamphetamine-induced locomotor sensitization in C57BL/6 mice. Psychopharmacology (Berl) (Jan), 231(1): 257-267.
- Adamah-Biassi EB, Zhang Y, Jung H, Vissapragada S, Miller RJ, Dubocovich Ml. (2014) Distribution of MT1 melatonin receptor promoter-driven RFP expression in the brains of BAC C3H/HeN transgenic mice. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society (Jan), 62(1): 70-84. doi:10.1369/0022155413507453
- Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, McGrath JC, Catterall WA, Spedding M, Peters JA, Harmar AJ, Abul-Hasn N, Anderson CM, Anderson CM, Araiksinen MS, Arita M, Arthofer E, Barker EL, Barratt C, Barnes NM, Bathgate R, Beart PM, Belelli D, Bennett AJ, Birdsall NJ, Boison D, Bonner TI, Brailsford L, Bröer S, Brown P, Calo G, Carter WG, Catterall WA, Chan SL, Chao MV, Chiang N, Christopoulos A, Chun JJ, Cidlowski J, Clapham DE, Cockcroft S, Connor MA, Cox HM, Cuthbert A, Dautzenberg FM, Davenport AP, Dawson PA, Dent G, Dijksterhuis JP, Dollery CT, Dolphin AC, Donowitz M, Dubocovich ML, Eiden L, Eidne K, Evans BA, Fabbro D, Fahlke C, Farndale R, Fitzgerald GA, Fong TM, Fowler CJ, Fry JR, Funk CD, Futerman AH, Ganapathy V, Gaisnier B, Gershengorn MA, Goldin A, Goldman ID, Gundlach AL, Hagenbuch B, Hales TG, Hammond JR, Hamon M, Hancox JC, Hauger RL, Hay DL, Hobbs AJ, Hollenberg MD, Holliday ND, Hoyer D, Hynes NA, Inui KI, Ishii S, Jacobson KA, Jarvis GE, Jarvis MF, Jensen R, Jones CE, Jones RL, Kaibuchi K, Kanai Y, Kennedy C, Kerr ID, Khan AA, Klienz MJ, Kukkonen JP, Lapoint JY, Leurs R, Lingueglia E, Lippiat J, Lolait SJ, Lummis SC, Lynch JW, MacEwan D, Maguire JJ, Marshall IL, May JM, McArdle CA, McGrath JC, Michel MC, Millar NS, Miller LJ, Mitolo V, Monk PN, Moore PK, Moorhouse AJ, Mouillac B, Murphy PM, Neubig RR, Neumaier J, Niesler B, Obaidat A, Offermanns S, Ohlstein E, Panaro MA, Parsons S, Pwrtwee RG, Petersen J, Pin JP, Poyner DR, Prigent S, Prossnitz ER, Pyne NJ, Pyne S, Quigley JG, Ramachandran R, Richelson EL, Roberts RE, Roskoski R, Ross RA, Roth M, Rudnick G, Ryan RM, Said SI, Schild L, Sanger GJ, Scholich K, Schousboe A, Schulte G, Schulz S, Serhan CN, Sexton PM, Sibley DR, Siegel JM, Singh G, Sitsapesan R, Smart TG, Smith DM, Soga T, Stahl A, Stewart G, Stoddart LA, Summers RJ, Thorens B, Thwaites DT, Toll L, Traynor JR, Usdin TB, Vandenberg RJ, Villalon C, Vore M, Waldman SA, Ward DT, Willars GB, Wonnacott SJ, Wright E, Ye RD, Yonezawa A, Zimmermann M. (2013) The Concise Guide to PHARMACOLOGY 2013/14: overview. Br J Pharmacol (Dec), 170(8): 1449-1458.
- Liu J, Somera-Molina KC, Hudson RL, Dubocovich ML. (2013) Melatonin potentiates running wheel-induced neurogenesis in the dentate gyrus of adult C3H/HeN mice hippocampus. J Pineal Res (Mar), 54(2): 222-231.
- Adamah-Biassi EB, Stepien I, Hudson RL, Dubocovich ML. (2013) Automated Video Analysis System Reveals Distinct Diurnal Behaviors in C57BL/6 and C3H/HeN Mice. Behav Brain Res (Jan).
- Hutchinson AJ, Hudson RL, Dubocovich ML. (2012) Genetic deletion of MT(1) and MT(2) melatonin receptors differentially abrogates the development and expression of methamphetamine-induced locomotor sensitization during the day and the night in C3H/HeN mice. J Pineal Res (Nov), 53(4): 399-409.
- Hutchinson AJ, Hudson RL, Dubocovich ML. (2012) Genetic deletion of MT(1) and MT(2) melatonin receptors differentially abrogates the development and expression of methamphetamine-induced locomotor sensitization during the day and the night in C3H/HeN mice. J Pineal Res (Nov), 53(4): 399-409.
- Liu J, Somera-Molina KC, Hudson R,Dubocovich ML. (2012) Melatonin potentiates running wheel-induced neurogenesis in the dentate gyrus of adult C3H/HeN mice hippocampus. J Pineal Res (Nov), 53(4).
- HUTCHINSON, A., HUDSON, R.L., DUBOCOVICH, M.L. (2012) Methamphetamine-induced development and expression of locomotor sensitization is differentially modulated by the MT1 and/or MT2 melatonin receptors in C3H/HeN mice during the light and dark phases. Journal of Pineal Research (Jan).
- Rawashdeh O, Hudson RL, Stepien I, Dubocovich ML. (2011) Circadian periods of sensitivity for ramelteon on the onset of running-wheel activity and the peak of suprachiasmatic nucleus neuronal firing rhythms in C3H/HeN mice. Chronobiol Int (Feb), 28(1): 31-38.
- Dubocovich ML, Delagrange P., Krause D.N., Sugden D., Cardinali D.P., Olcese J. (2010) International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, Classification, and Pharmacology of G Protein-Coupled Melatonin Receptors. Pharmacological Reviews (Sep), 62: 343-380.
- Dubocovich ML, Delagrange P, Krause DN., Sugden D, Cardinali DP, Olcese J. (2010) International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, Classification and Pharmacology of G Protein-Coupled Melatonin Receptors. Pharmacological Reviews (Jan), 62: 343-380.
- Dubocovich ML. (2007) Melatonin receptors: role on sleep and circadian rhythm regulation. Sleep Med (Dec), 8 Sup: 34-42.
- Masana MI, Sumaya IC, Becker-Andre M, Dubocovich ML, Dubocovich M. (2007) Behavioral characterization and modulation of circadian rhythms by light and melatonin in C3H/HeN mice homozygous for the RORbeta knockout. Am J Physiol Regul Integr Comp Physiol (Jun), 292(6): 2357-2367.
- Dubocovich ML. (2006) Agomelatine targets a range of major depressive disorder symptoms. Curr Opin Investig Drugs (Jul), 7(7): 670-680.
- Blask DE, Brainard GC, Dauchy RT, Hanifin JP, Davidson LK, Krause JA, Sauer LA, Rivera-Bermudez MA, Dubocovich ML, Jasser SA, Lynch DT, Rollag MD, Zalatan F. (2005) Melatonin-depleted blood from premenopausal women exposed to light at night stimulates growth of human breast cancer xenografts in nude rats. Cancer Res (Dec), 65(23): 11174-11184.
- Mundey K, Benloucif S, Harsanyi K, Dubocovich ML, Zee PC. (2005) Phase-dependent treatment of delayed sleep phase syndrome with melatonin. Sleep (Oct), 28(10): 1271-1278.
- Sumaya IC, Masana MI, Dubocovich ML. (2005) The antidepressant-like effect of the melatonin receptor ligand luzindole in mice during forced swimming requires expression of MT2 but not MT1 melatonin receptors. J Pineal Res (Sep), 39(2): 170-177.
- Dubocovich ML, Hudson RL, Sumaya IC, Masana MI, Manna E. (2005) Effect of MT1 melatonin receptor deletion on melatonin-mediated phase shift of circadian rhythms in the C57BL/6 mouse. J Pineal Res (Sep), 39(2): 113-120.
- Dubocovich ML, Markowska M. (2005) Functional MT1 and MT2 melatonin receptors in mammals. Endocrine (Jul), 27(2): 101-110.
- Hansen M, Janssen I, Schiff A, Zee PC, Dubocovich ML. (2005) The impact of school daily schedule on adolescent sleep. Pediatrics (Jun), 115(6): 1555-1561.
- Masana MI, Soares JM, Dubocovich ML. (2005) 17Beta-estradiol modulates hMT1 melatonin receptor function. Neuroendocrinology (Apr), 81(2): 87-95.
- Gerdin MJ, Masana MI, Rivera-Bermúdez MA, Hudson RL, Earnest DJ, Gillette MU, Dubocovich ML. (2004) Melatonin desensitizes endogenous MT2 melatonin receptors in the rat suprachiasmatic nucleus: relevance for defining the periods of sensitivity of the mammalian circadian clock to melatonin. FASEB J (Nov), 18(14): 1646-1656.
- Gerdin MJ, Masana MI, Dubocovich ML. (2004) Melatonin-mediated regulation of human MT(1) melatonin receptors expressed in mammalian cells. Biochem Pharmacol (Jun), 67(11): 2023-2030.
- Rivera-Bermúdez MA, Masana MI, Brown GM, Earnest DJ, Dubocovich ML. (2004) Immortalized cells from the rat suprachiasmatic nucleus express functional melatonin receptors. Brain Res (Mar), 1002(1-2): 21-27.
- Dubocovich ML, Rivera-Bermudez MA, Gerdin MJ, Masana MI. (2003) Molecular pharmacology, regulation and function of mammalian melatonin receptors. Front Biosci (Sep), 8: 1093-1108.
- Soares JM, Masana MI, Ersahin C, Dubocovich ML. (2003) Functional melatonin receptors in rat ovaries at various stages of the estrous cycle. J Pharmacol Exp Ther (Aug), 306(2): 694-702.
- Gerdin MJ, Mseeh F, Dubocovich ML. (2003) Mutagenesis studies of the human MT2 melatonin receptor. Biochem Pharmacol (Jul), 66(2): 315-320.
- Rivera-Bermúdez MA, Gerdin MJ, Earnest DJ, Dubocovich ML. (2003) Regulation of basal rhythmicity in protein kinase C activity by melatonin in immortalized rat suprachiasmatic nucleus cells. Neurosci Lett (Jul), 346(1-2): 37-40.
- Benloucif S, Masana MI, Zee PC, Dubocovich ML. (2003) Nimodipine potentiates light-induced phase shifts of circadian activity rhythms but not c-fos expression in the suprachiasmatic nucleus of mice. Brain Res (Mar), 966(1): 157-161.
- Gerdin MJ, Masana MI, Ren D, Miller RJ, Dubocovich ML. (2003) Short-term exposure to melatonin differentially affects the functional sensitivity and trafficking of the hMT1 and hMT2 melatonin receptors. J Pharmacol Exp Ther (Mar), 304(3): 931-939.
- Masana MI, Witt-Enderby PA, Dubocovich ML. (2003) Melatonin differentially modulates the expression and function of the hMT1 and hMT2 melatonin receptors upon prolonged withdrawal. Biochem Pharmacol (Mar), 65(5): 731-739.
- Masana MI, Doolen S, Ersahin C, Al-Ghoul WM, Duckles SP, Dubocovich ML, Krause DN. (2002) MT(2) melatonin receptors are present and functional in rat caudal artery. J Pharmacol Exp Ther (Sep), 302(3): 1295-1302.
- Mseeh F, Gerdin MJ, Dubocovich MI. (2002) Identification of cysteines involved in ligand binding to the human melatonin MT(2) receptor. European journal of pharmacology (Aug), 449(1-2): 29-38.
- Yuan L, Collins AR, Dai J, Dubocovich ML, Hill SM. (2002) MT(1) melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breast cancer cells. Mol Cell Endocrinol (Jun), 192(1-2): 147-156.
- Pappolla MA, Simovich MJ, Bryant-Thomas T, Chyan YJ, Poeggeler B, Dubocovich M, Bick R, Perry G, Cruz-Sanchez F, Smith MA. (2002) The neuroprotective activities of melatonin against the Alzheimer beta-protein are not mediated by melatonin membrane receptors. Journal of pineal research (Apr), 32(3): 135-42.
- Ersahin C, Masana MI, Dubocovich ML. (2002) Constitutively active melatonin MT(1) receptors in male rat caudal arteries. Eur J Pharmacol (Mar), 439(1-3): 171-172.
- Lotufo CM, Lopes C, Dubocovich ML, Farsky SH, Markus RP. (2001) Melatonin and N-acetylserotonin inhibit leukocyte rolling and adhesion to rat microcirculation. Eur J Pharmacol (Nov), 430(2-3): 351-357.
- Masana MI, Dubocovich ML. (2001) Melatonin receptor signaling: finding the path through the dark. Sci STKE (Nov), 2001(107): 39-39.
- Reid KJ, Chang AM, Dubocovich ML, Turek FW, Takahashi JS, Zee PC. (2001) Familial advanced sleep phase syndrome. Arch Neurol (Jul), 58(7): 1089-1094.
- Hunt AE, Al-Ghoul WM, Gillette MU, Dubocovich ML. (2001) Activation of MT(2) melatonin receptors in rat suprachiasmatic nucleus phase advances the circadian clock. Am J Physiol Cell Physiol (Jan), 280(1): 110-118.
- Masana MI, Benloucif S, Dubocovich ML. (2000) Circadian rhythm of mt1 melatonin receptor expression in the suprachiasmatic nucleus of the C3H/HeN mouse. J Pineal Res (Apr), 28(3): 185-192.
- Ruby NF, Dubocovich ML, Heller HC. (2000) Siberian hamsters that fail to reentrain to the photocycle have suppressed melatonin levels. Am J Physiol Regul Integr Comp Physiol (Mar), 278(3): 757-762.
- Benloucif S, Bauer GL, Dubocovich ML, Finkel SI, Zee PC. (1999) Nimodipine potentiates the light-induced suppression of melatonin. Neurosci Lett (Sep), 272(1): 67-71.
- Benloucif S, Masana MI, Yun K, Dubocovich ML. (1999) Interactions between light and melatonin on the circadian clock of mice. J Biol Rhythms (Aug), 14(4): 281-289.
- Dubocovich ML, Masana MI, Benloucif S. (1999) Molecular pharmacology and function of melatonin receptor subtypes. Adv Exp Med Biol (Jan), 460: 181-190.
- Al-Ghoul WM, Herman MD, Dubocovich ML. (1998) Melatonin receptor subtype expression in human cerebellum. Neuroreport (Dec), 9(18): 4063-4068.
- Dubocovich ML, Yun K, Al-Ghoul WM, Benloucif S, Masana MI. (1998) Selective MT2 melatonin receptor antagonists block melatonin-mediated phase advances of circadian rhythms. FASEB J (Sep), 12(12): 1211-1220.
- Witt-Enderby PA, Masana MI, Dubocovich ML. (1998) Physiological exposure to melatonin supersensitizes the cyclic adenosine 3',5'-monophosphate-dependent signal transduction cascade in Chinese hamster ovary cells expressing the human mt1 melatonin receptor. Endocrinology (Jul), 139(7): 3064-3071.
- Beresford IJ, Browning C, Starkey SJ, Brown J, Foord SM, Coughlan J, North PC, Dubocovich ML, Hagan RM. (1998) GR196429: a nonindolic agonist at high-affinity melatonin receptors. J Pharmacol Exp Ther (Jun), 285(3): 1239-1245.
- Doolen S, Krause DN, Dubocovich ML, Duckles SP. (1998) Melatonin mediates two distinct responses in vascular smooth muscle. Eur J Pharmacol (Mar), 345(1): 67-69.
- Benloucif S, Masana MI, Dubocovich ML. (1997) Responsiveness to melatonin and its receptor expression in the aging circadian clock of mice. Am J Physiol (Dec), 273(6 Pt): 1855-1860.
- Dubocovich ML, Masana MI, Iacob S, Sauri DM. (1997) Melatonin receptor antagonists that differentiate between the human Mel1a and Mel1b recombinant subtypes are used to assess the pharmacological profile of the rabbit retina ML1 presynaptic heteroreceptor. Naunyn Schmiedebergs Arch Pharmacol (Mar), 355(3): 365-375.
- Benloucif S, Masana MI, Dubocovich ML. (1997) Light-induced phase shifts of circadian activity rhythms and immediate early gene expression in the suprachiasmatic nucleus are attenuated in old C3H/HeN mice. Brain Res (Jan), 747(1): 34-42.
- Masana MI, Benloucif S, Dubocovich ML. (1996) Light-induced c-fos mRNA expression in the suprachiasmatic nucleus and the retina of C3H/HeN mice. Brain Res Mol Brain Res (Dec), 42(2): 193-201.
- Jansen JM, Copinga S, Gruppen G, Molinari EJ, Dubocovich ML, Grol CJ. (1996) The high affinity melationin binding site probed with conformationally restricted ligand--I. Pharmacophore and minireceptor models. Bioorg Med Chem (Aug), 4(8): 1321-1332.
- Witt-Enderby PA, Dubocovich ML. (1996) Characterization and regulation of the human ML1A melatonin receptor stably expressed in Chinese hamster ovary cells. Mol Pharmacol (Jul), 50(1): 166-174.
- Benloucif S, Dubocovich ML. (1996) Melatonin and light induce phase shifts of circadian activity rhythms in the C3H/HeN mouse. J Biol Rhythms (Jun), 11(2): 113-125.
- Molinari EJ, North PC, Dubocovich ML. (1996) 2-[125I]iodo-5-methoxycarbonylamino-N-acetyltryptamine: a selective radioligand for the characterization of melatonin ML2 binding sites. Eur J Pharmacol (Apr), 301(1-3): 159-168.
- Larson-Prior LJ, Siuciak JA, Dubocovich ML. (1996) Localization of 2-[125I]iodomelatonin binding sites in visual areas of the turtle brain. Eur J Pharmacol (Feb), 297(1-2): 181-185.
- Dubocovich ML, Benloucif S, Masana MI. (1996) Melatonin receptors in the mammalian suprachiasmatic nucleus. Behav Brain Res (Jan), 73(1-2): 141-147.
- Dubocovich ML. (1995) Melatonin receptors: are there multiple subtypes?. Trends Pharmacol Sci (Feb), 16(2): 50-56.
- Popova JS, Dubocovich ML. (1995) Melatonin receptor-mediated stimulation of phosphoinositide breakdown in chick brain slices. J Neurochem (Jan), 64(1): 130-138.
- Masana MI, Brown RC, Pu H, Gurney ME, Dubocovich ML. (1995) Cloning and characterization of a new member of the G-protein coupled receptor EDG family. Receptors Channels (Jan), 3(4): 255-262.
- Krause DN, Siuciak JA, Dubocovich ML. (1994) Unilateral optic nerve transection decreases 2-[125I]-iodomelatonin binding in retinorecipient areas and visual pathways of chick brain. Brain Res (Aug), 654(1): 63-74.
- Copinga S, Tepper PG, Grol CJ, Horn AS, Dubocovich ML. (1993) 2-Amido-8-methoxytetralins: a series of nonindolic melatonin-like agents. J Med Chem (Oct), 36(20): 2891-2898.
- Carneiro RC, Markus RP, Dubocovich ML. (1993) 2-[125I]iodomelatonin binding sites in the rat vas deferens. Biol Signals (Jul), 2(4): 194-198.
- Pang SF, Dubocovich ML, Brown GM. (1993) Melatonin receptors in peripheral tissues: a new area of melatonin research. Biol Signals (Jul), 2(4): 177-180.
- Carneiro RC, Markus RP, Dubocovich ML. (1993) Presynaptic modulation by melatonin of the nicotine-induced calcium-dependent release of norepinephrine from rat vas deferens. Biol Signals (Jul), 2(4): 199-206.
- Siuciak JA, Dubocovich ML. (1993) Effect of pinealectomy and the light/dark cycle on 2-[125I]iodomelatonin binding in the chick optic tectum. Cell Mol Neurobiol (Jun), 13(3): 193-202.
- Krause DN, Siuciak JA, Dubocovich ML. (1992) Optic nerve transection decreases 2-[125I]iodomelatonin binding in the chick optic tectum. Brain Res (Sep), 590(1-2): 325-328.
- Siuciak JA, Gamache PH, Dubocovich ML. (1992) Monoamines and their precursors and metabolites in the chicken brain, pineal, and retina: regional distribution and day/night variations. J Neurochem (Feb), 58(2): 722-729.
- Siuciak JA, Krause DN, Dubocovich ML. (1991) Quantitative pharmacological analysis of 2-125I-iodomelatonin binding sites in discrete areas of the chicken brain. J Neurosci (Sep), 11(9): 2855-2864.
- Stanton TL, Siuciak JA, Dubocovich ML, Krause DN. (1991) The area of 2-[125I] iodomelatonin binding in the pars tuberalis of the ground squirrel is decreased during hibernation. Brain Res (Aug), 557(1-2): 285-288.
- Blazynski C, Dubocovich ML. (1991) Localization of 2-[125I]iodomelatonin binding sites in mammalian retina. J Neurochem (Jun), 56(6): 1873-1880.
- Dubocovich ML. (1991) Melatonin receptors in the central nervous system. Adv Exp Med Biol (Jan), 294: 255-265.
- Krause DN, Dubocovich ML. (1991) Melatonin receptors. Annu Rev Pharmacol Toxicol (Jan), 31: 549-568.
- Krause DN, Dubocovich ML. (1990) Regulatory sites in the melatonin system of mammals. Trends Neurosci (Nov), 13(11): 464-470.
- Fang JM, Dubocovich ML. (1990) Activation of melatonin receptor sites retarded the depletion of norepinephrine following inhibition of synthesis in the C3H/HeN mouse hypothalamus. J Neurochem (Jul), 55(1): 76-82.
- Dubocovich ML, Mogilnicka E, Areso PM. (1990) Antidepressant-like activity of the melatonin receptor antagonist, luzindole (N-0774), in the mouse behavioral despair test. Eur J Pharmacol (Jul), 182(2): 313-325.
- Siuciak JA, Fang JM, Dubocovich ML. (1990) Autoradiographic localization of 2-[125I]iodomelatonin binding sites in the brains of C3H/HeN and C57BL/6J strains of mice. Eur J Pharmacol (May), 180(2-3): 387-390.
- Duncan MJ, Fang JM, Dubocovich ML. (1990) Effects of melatonin agonists and antagonists on reproduction and body weight in the Siberian hamster. J Pineal Res (Jan), 9(4): 231-242.
- Dubocovich ML. (1990) Presynaptic receptors in the visual system. Ann N Y Acad Sci (Jan), 604: 82-95.
- Duncan MJ, Takahashi JS, Dubocovich ML. (1989) Characteristics and autoradiographic localization of 2-[125I]iodomelatonin binding sites in Djungarian hamster brain. Endocrinology (Aug), 125(2): 1011-1018.
- Timmerman W, Dubocovich ML, Westerink BH, De Vries JB, Tepper PG, Horn AS. (1989) The enantiomers of the dopamine agonist N-0437: in vivo and in vitro effects on the release of striatal dopamine. Eur J Pharmacol (Jul), 166(1): 1-11.
- Dubocovich ML, Shankar G, Mickel M. (1989) 2-[125I]iodomelatonin labels sites with identical pharmacological characteristics in chicken brain and chicken retina. Eur J Pharmacol (Mar), 162(2): 289-299.
- Watson JM, Vogel SM, Cotterell DJ, Dubocovich ML. (1988) Cholinergic antagonism of beta-adrenergic stimulated action potentials and adenylate cyclase activity in rabbit ventricular cardiomyocytes. Eur J Pharmacol (Oct), 155(1-2): 101-108.
- Dubocovich ML. (1988) Luzindole (N-0774): a novel melatonin receptor antagonist. J Pharmacol Exp Ther (Sep), 246(3): 902-910.
- Dubocovich ML. (1988) Pharmacology and function of melatonin receptors. FASEB J (Sep), 2(12): 2765-2773.
- Eells JT, Dubocovich ML. (1988) Pyrethroid insecticides evoke neurotransmitter release from rabbit striatal slices. J Pharmacol Exp Ther (Aug), 246(2): 514-521.
- Hensler JG, Dubocovich ML. (1988) GABAergic modulation of D-1 dopamine receptor-mediated 3H-acetylcholine release from rabbit retina. Naunyn Schmiedebergs Arch Pharmacol (Jun), 337(6): 661-668.
- Duncan MJ, Takahashi JS, Dubocovich ML. (1988) 2-[125I]iodomelatonin binding sites in hamster brain membranes: pharmacological characteristics and regional distribution. Endocrinology (May), 122(5): 1825-1833.
- Van der Weide J, De Vries JB, Tepper PG, Krause DN, Dubocovich ML, Horn AS. (1988) N-0437: a selective D-2 dopamine receptor agonist in in vitro and in vivo models. Eur J Pharmacol (Mar), 147(2): 249-258.
- Van der Weide J, Tendijck ME, Tepper PG, De Vries JB, Dubocovich ML, Horn AS. (1988) The enantiomers of the D-2 dopamine receptor agonist N-0437 discriminate between pre- and postsynaptic dopamine receptors. Eur J Pharmacol (Feb), 146(2-3): 319-326.
- Hensler JG, Cotterell DJ, Dubocovich ML. (1987) Pharmacological and biochemical characterization of the D-1 dopamine receptor mediating acetylcholine release in rabbit retina. J Pharmacol Exp Ther (Dec), 243(3): 857-867.
- Dubocovich ML, Takahashi JS. (1987) Use of 2-[125I]iodomelatonin to characterize melatonin binding sites in chicken retina. Proc Natl Acad Sci U S A (Jun), 84(11): 3916-3920.
- Duncan MJ, Takahashi JS, Dubocovich ML. (1986) Characterization of 2-[125I]iodomelatonin binding sites in hamster brain. Eur J Pharmacol (Dec), 132(2-3): 333-334.
- Hensler JG, Dubocovich ML. (1986) D1-dopamine receptor activation mediates [3H]acetylcholine release from rabbit retina. Brain Res (Nov), 398(2): 407-412.
- Dubocovich ML, Hensler JG. (1986) Modulation of [3H]-dopamine released by different frequencies of stimulation from rabbit retina. Br J Pharmacol (May), 88(1): 51-61.
- Dubocovich ML. (1985) Characterization of a retinal melatonin receptor. J Pharmacol Exp Ther (Aug), 234(2): 395-401.
- García-Sevilla JA, Dubocovich ML, Langer SZ. (1985) Interaction between presynaptic facilitatory angiotensin II receptors and inhibitory muscarinic cholinoceptors on 3H-noradrenaline release in the rabbit heart. Naunyn Schmiedebergs Arch Pharmacol (Jul), 330(1): 9-15.
- Dubocovich ML, Lucas RC, Takahashi JS. (1985) Light-dependent regulation of dopamine receptors in mammalian retina. Brain Res (Jun), 335(2): 321-325.
- Dubocovich ML, Weiner N. (1985) Pharmacological differences between the D-2 autoreceptor and the D-1 dopamine receptor in rabbit retina. J Pharmacol Exp Ther (Jun), 233(3): 747-754.
- Dubocovich ML, Zahniser NR. (1985) Binding characteristics of the dopamine uptake inhibitor [3H]nomifensine to striatal membranes. Biochem Pharmacol (Apr), 34(8): 1137-1144.
- Scatton B, Dubois A, Dubocovich ML, Zahniser NR, Fage D. (1985) Quantitative autoradiography of 3H-nomifensine binding sites in rat brain. Life Sci (Mar), 36(9): 815-822.
- Dubocovich ML. (1984) N-Acetyltryptamine antagonizes the melatonin-induced inhibition of [3H]dopamine release from retina. Eur J Pharmacol (Oct), 105(1-2): 193-194.
- Dubocovich ML. (1984) Modulation of [3H]dopamine release from rabbit retina. Fed Proc (Sep), 43(12): 2714-2718.
- Dubocovich ML. (1984) Alpha-2 adrenoceptors modulate [3H]dopamine release from rabbit retina. J Pharmacol Exp Ther (Jul), 230(1): 149-155.
- Dubocovich ML. (1984) Presynaptic alpha-adrenoceptors in the central nervous system. Ann N Y Acad Sci (Jan), 430: 7-25.
- Dubocovich ML. (1983) Melatonin is a potent modulator of dopamine release in the retina. Nature (Dec), 306(5945): 782-784.
- Zahniser NR, Dubocovich ML. (1983) Comparison of dopamine receptor sites labeled by [3H]-S-sulpiride and [3H]-spiperone in striatum. J Pharmacol Exp Ther (Dec), 227(3): 592-599.
- Dubocovich ML, Weiner N. (1983) Enkephalins modulate [3H]dopamine release from rabbit retina in vitro. J Pharmacol Exp Ther (Mar), 224(3): 634-639.
- Barnes JS, Dubocovich ML, Nies AS, Gerber JG. (1982) Lack of interaction between tricyclic antidepressants and clonidine at the alpha 2-adrenoceptor on human platelets. Clin Pharmacol Ther (Dec), 32(6): 744-748.
- Galzin AM, Dubocovich ML, Langer SZ. (1982) Presynaptic inhibition by dopamine receptor agonists of noradrenergic neurotransmission in the rabbit hypothalamus. J Pharmacol Exp Ther (May), 221(2): 461-471.
- Dubocovich ML, Weiner N. (1981) Modulation of the stimulation-evoked release of [3H]dopamine in the rabbit retina. J Pharmacol Exp Ther (Dec), 219(3): 701-707.
- Massingham R, Dubocovich ML, Shepperson NB, Langer SZ. (1981) In vivo selectivity of prazosin but not of WB4101 for postsynaptic alpha-1 adrenoceptors. J Pharmacol Exp Ther (May), 217(2): 467-474.
- Langer SZ, Dubocovich ML. (1981) Cocaine and amphetamine antagonize the decrease of noradrenergic neurotransmission elicited by oxymetazoline but potentiate the inhibition by alpha-methylnorepinephrine in the perfused cat spleen. J Pharmacol Exp Ther (Jan), 216(1): 162-171.
- Langer SZ, Moret C, Raisman R, Dubocovich ML, Briley M. (1980) High-affinity [3H]imipramine binding in rat hypothalamus: association with uptake of serotonin but not of norepinephrine. Science (Dec), 210(4474): 1133-1135.
- Dubocovich ML, Langer SZ. (1980) Pharmacological differentiation of presynaptic inhibitory alpha-adrenoceptors and opiate receptors in the cat nictitating membrane. Br J Pharmacol (Nov), 70(3): 383-393.
- Massingham R, Dubocovich ML, Langer SZ. (1980) The role of presynaptic receptors in the cardiovascular actions of N,N-di-n-propyldopamine in the cat and dog. Naunyn Schmiedebergs Arch Pharmacol (Oct), 314(1): 17-28.
- Pelayo F, Dubocovich ML, Langer SZ. (1980) Inhibition of neuronal uptake reduces the presynaptic effects of clonidine but not of alpha-methylnoradrenaline on the stimulation-evoked release of 3H-noradrenaline from rat occipital cortex slices. Eur J Pharmacol (Jun), 64(2-3): 143-155.
- Dubocovich ML, Langer SZ, Massingham R. (1980) Lack of correlation between presynaptic inhibition of noradrenaline release and end organ responses during nerve stimulation. Br J Pharmacol (May), 69(1): 81-90.
- Dubocovich ML, Garcia-Sevilla JA, Langer SZ, Massingham R. (1980) Experimental renal hypertension and [3H]-noradrenaline release from the rabbit hypothalamus: enhanced K+-evoked overflow of tritium and lack of facilitation through presynaptic angiotensin II receptors [proceedings]. Br J Pharmacol (Jan), 68(1): 112-113.
- Dubocovich ML, Langer SZ. (1980) Dopamine and alpha adrenoceptor agonists inhibit neurotransmission in the cat spleen through different presynaptic receptors. J Pharmacol Exp Ther (Jan), 212(1): 144-152.
- Massingham R, Dubocovich ML, Langer SZ. (1979) Effect of the alpha-adrenoreceptor agonist LD 3098 (cirazoline) on the magnitude of end-organ responses induced by nerve stimulation and exogenous noradrenaline in a variety of sympathetically innervated animal tissues. Clin Sci (Lond) (Dec), 57 Su: 185-187.
- Dubocovich ML, Langer SZ, Pelayo F. (1979) Cocaine and desipramine antagonize the clonidine-induced inhibition of [3H]-noradrenaline release from the rat cerebral cortex [proceedings]. Br J Pharmacol (Nov), 67(3): 417-418.
- Scatton B, Pelayo F, Dubocovich ML, Langer SZ, Bartholini G. (1979) Effect of clonidine on utilization and potassium-evoked release of adrenaline in rat brain areas. Brain Res (Oct), 176(1): 197-201.
- Dubocovich ML, Langer SZ, Moret C. (1979) Antagonism by (+)-amphetamine of the inhibition of [3H]-noradrenaline overflow obtained by alpha-adrenoceptor agonists or bretylium in the perfused cat spleen [proceedings]. Br J Pharmacol (Jul), 66(3): 460-461.
- Garcia-Sevilla JA, Dubocovich ML, Langer SZ. (1979) Angiotensin II facilitates the potassium-evoked release of 3H-noradrenaline from the rabbit hypothalamus. Eur J Pharmacol (Jun), 56(1-2): 173-176.
- Arbilla S, Briley MS, Dubocovich ML, Langer SZ. (1978) Neuroleptic binding and their effects on the spontaneous and potassium-evoked release of 3H-dopamine from the striatum and of 3H-noradrenaline from the cerebral cortex. Life Sci (Oct), 23(17-18): 1775-1780.
- Pelayo F, Dubocovich ML, Langer SZ. (1978) Possible role of cyclic nucleotides in regulation of noradrenaline release from rat pineal through presynaptic adrenoceptors. Nature (Jul), 274(5666): 76-78.
- Celuch SM, Dubocovich ML, Lander SZ. (1978) Stimulation of presynaptic beta-adrenoceptors enhances [3H]-noradrenaline release druing nerve stimulation in the perfused cat spleen. Br J Pharmacol (May), 63(1): 97-109.
- Dubocovich ML, Langer SZ, Pelayo F. (1978) Effect of cyclic nucleotides on [3H]-neurotransmitter release induced by potassium stimulation in the rat pineal gland [proceedings]. Br J Pharmacol (Mar), 62(3): 383-384.
- Pelayo F, Dubocovich ML, Langer SZ. (1977) Regulation of noradrenaline release in the rat pineal through a negative feedback mechanism mediated by presynaptic alpha-adrenoceptors. Eur J Pharmacol (Oct), 45(3): 317-318.
- Langer SZ, Dubocovich ML. (1977) Subsensitivity of presynaptic alpha-adrenoceptors after exposure to noradrenaline. Eur J Pharmacol (Jan), 41(1): 87-88.
- Dubocovich ML, Langer SZ. (1976) Influence of the frequency of nerve stimulation on the metabolism of 3H-norepinephrine released from the perfused cat spleen: differences observed during and after the period of stimulation. J Pharmacol Exp Ther (Jul), 198(1): 83-101.
- Dubocovich ML, Langer SZ. (1975) Evidence against a physiological role of prostaglandins in the regulation of noradrenaline release in the cat spleen. J Physiol (Oct), 251(3): 737-762.
- Dubocovich ML, Langer SZ. (1974) Negative feed-back regulation of noradrenaline release by nerve stimulation in the perfused cat's spleen: differences in potency of phenoxybenzamine in blocking the pre- and post-synaptic adrenergic receptors. J Physiol (Mar), 237(3): 505-519.
- Aikaterini Sakellaropouloua, Laura Ulrichb, Margarita L. Dubocovich, and Andrew Tsotninis. (1900) New, melatonin receptors selective 2-phenyl/C5-substituted ?-acylated tryptamines. Bioorganic and Medicinal Chemistry (Jan)
Books and Book Chapters:
- Dubocovich, ML. (2023) Melatonin, Light, and the Circadian System. In: Biological Implications of Circadian Disruption: A Modern Health Challenge. Editors: Randy Nelson and Laura Fonken. Cambridge University Press, 2023.
Professional Memberships:
- American College of Neuropsychopharmacology; Fellow (2013–present)
- Catecholamine Society (2011–present)
- American Association of Pharmacology Chairs (2009–present)
- European Circadian Rhythms Society (2009–present)
- Toxicology Research Center at UB; Member (2009–present)
- Northwestern University Clinical and Translational Sciences (NUCATS) Institute; Member, NUCATS Community Engagement and Research Center (2007–2008)
- Center for Drug Discovery and Chemical Biology (CDCCB); Core Faculty (2005–2008)
- College International of Neuropharmacology (CINP) (2004–2008)
- Society for Advancement of Chicanos and Native Americans in Science (SACNAS) (2002–present)
- American College of Neuropsychopharmacology; Member (1998–2012)
- Center for Circadian Biology and Medicine (CCB&M); Core Faculty (1996–2008)
- Buehler Center on Aging (BCA); Member (1995–2008)
- Melatonin Club (1994–2005)
- Asher Center for the Study and Treatment of Depressive Disorder; Member (1993–2008)
- Northwestern University Center for Biotechnology; Member (1992–2000)
- Robert H. Laurie Cancer Center; Member (1991–2008)
- International Society for Neurochemistry (1991–present)
- Catecholamine Club (1990–2011)
- European Pineal Society (1990–2009)
- Northwestern University Institute Neuroscience (NUIN); Charter Member (1989–2006)
- American Association Advancement of Science (1988–present)
- Serotonin Club (1987–present)
- American Heart Assoc - Chicago Area (1983–2000)
- Association for Research in Vision and Ophthalmology (1983–1987)
- Sigma Xi (1983–present)
- American Society for Pharmacology and Experimental Therapeutics (1983–present)
- Women in Neuroscience (1982–2010)
- American Association of Dental Schools (1982–1984)
- Society of Neuroscience (1981–present)
- French Association of Pharmacology (1979–1989)
- British Pharmacological Society; 1978–2005; 2016-pesent (1978–present)
- Argentine Society of Clinical Research (1974–1976)
- Latinoamerican Assoc. of Pharmacology (1974–1976)
- Argentine Society of Pharmacology (1973–1976)
Service Activities:
- ASPET Awards Committee; Member (2023–2026)
- (2022)
- Jacobs School Faculty Council; Member (2021–2022)
- UB Faculty Recruitment, Mentoring and Retention, Scholarship, Tenure and Recognition; Member (2021–present)
- MMJ | WKBW-TV Interview on the clinical trial “Melatonin for the treatment of COVID-19 patients”; MEDIA INTERVIEWS AND ARTICLES (2020–present)
- Spectrum TV, Buffalo- Interview on the clinical trial “Melatonin for the treatment of COVID-19 patients”; MEDIA INTERVIEWS AND ARTICLES (2020–present)
- WBFO Buffalo National Public Radio Interview on ”Virtual Discovery of Melatonin Receptor Ligands to Modulate Circadian Rhythms; MEDIA INTERVIEWS AND ARTICLES (2020–present)
- UB President Council on Race; Member (2020–present)
- ASPET Global Partnership Task Force (Member); Officer/Scientific Societies (2018–2019)
- Unit Diversity Officer; Member (2018–present)
- UB Research Featured as a ‘Paper of the Month’ [NIEHS, NIH] Popovska-Gorevski et al., 2017. [https://www.niehs.nih.gov/news/newsletter/2017/3/papers/dert/index.htm#a1].; MEDIA INTERVIEWS AND ARTICLES (2017–present)
- Chemicals in Insecticides Can Increase Risk of Diabetes. Multiple interviews for radios, news papers and publications across the word [http://medicine.buffalo.edu/departments/pharmtox/news-and-events/in-the- .host.html/content/shared/smbs/media/2017/01/dubocovich-melatonin-6830.detail.html].; MEDIA INTERVIEWS AND ARTICLES (2017–present)
- Founder and Leader of the Diversity and Inclusion Leaning Environment Committee; Founder and Leader (2017–present)
- Dubocovich Says Study Shows Exercise and Controlled Intake of Meth May be Powerful Addiction Treatment. multiple interviews for radios, news papers and publications across the word. http://medicine.buffalo.edu/departments/pharmtox/news-and-events/in-the-news.host.html/content/shared/ smbs/media/2016/10/dubocovich-meth-exercise-6570-7.detail.html; MEDIA INTERVIEWS AND ARTICLES (2016–present)
- British Journal of Pharmacology Themed Issue on Melatonin Editors: Claire Stanford, PhD & Margarita L. Dubocovich, PhD; Theme Issue Editor (2016)
- ASPET Mentoring and Career Development Committee (Member); Officer/Scientific Societies (2015–2017)
- Developmental Brain Research (2015)
- WBFO Buffalo National Public Radio Interview with Mike Desmond on “Environmental chemicals that may boost diabetes risk by disrupting circadian rhythms are being studied at UB” http://www.buffalo.edu/news/releases/2014/08/005.html.; MEDIA INTERVIEWS AND ARTICLES (2014–present)
- Steering Committee - Clinical and Translational Science Award Hub.; Member (2014–present)
- BPAC PhRMA Foundation Annual Review Panel: starter grants and fellowships (Member); Study Section Member (2013)
- iSEED Executive Committee (Chair) – (iSEED Co-Director); Chair and Co Director (2013–present)
- SEED Steering Committee (Ex Officio) - (iSEED Co-Director); Ex Officio iSEED Co-Director (2013–present)
- Special Emphasis Panel/Scientific Review Group: (ZGM1 MBRS-Y) (Member)(03/13/12); Study Section Member (2012)
- NIH Summer Research Experience Programs: (ZMH1 ERB-X)(Member)(10/20/11); Study Section Member (2011)
- Catecholamine Society: Councilor (2011-2016); Officer/Scientific Societies (2011–2016)
- Neuropharmacology International (2011)
- Diversity Subcommittee Faculty Council, School of Medicine and Biomedical Sciences; Member (2011–present)
- Officer/Scientific Societies - Upstate New York ASPET Chapter - Pharmacology Society (UNYPS); Founder (2010), President (2012) and Past President (2013) (2010–2014)
- UB Task Force on Graduate Diversity; Chair (2010–present)
- NINDS R13/U13 Conference Grant Review (12/2009) (Consultant); Study Section Member (2009)
- Neuropharmacology Study Section, (CSR/NIH) (Consultant) (06/01/09); Study Section Member (2009)
- Officer/Scientific Societies - Professional Development Committee, Society for Neuroscience.; Committee Member (2009–2011)
- Officer/Scientific Societies - Diversity In Neuroscience (DIN) Committee, Society for Neuroscience; Committee Member (2008–2009)
- International Journal Neuropharmacology (2007)
- Special Emphasis Panel, IFCN-D 02 (CSR/NIH) (Member) (07/25/06).; Study Section Member (2006)
- Officer/Scientific Societies - Division for Neuropharmacology of ASPET - Elect (2006); Active (2007-2010); Secretary/Treasurer (2006–2010)
- Chronobiology International (2006)
- Journal of Pineal Research, Blackwell Publishing. (Editor in Chief: Dr. Russel Reiter); Member (2006)
- Channel 2, 9 and CLTV evening news. Feature in JAMA, Science Magazine, Chicago Tribune, La Nacion (Argentina) and other international newspapers on the paper by Hansen et al., 2005 on “The Impact of School Daily Schedule on Adolescent Sleep”.; MEDIA INTERVIEWS AND ARTICLES (2005–present)
- Special Emphasis Panel, reviewing grant applications on Potential long term effects of stimulant ADHD treatments in non-human primates (Member); Study Section Member (2005)
- Officer/Scientific Societies - Great Lakes Chapter ASPET; Committee Member (2005–2007)
- International Organizing Committee. College International Neuropsychopharmacology (CINP) Meeting, Chicago, USA (July 2006) (Member); Officer/Scientific Societies (2004–2006)
- International Organizing Committee of Latinoamerican Congress of Pharmacology, Caracas, Venezuela (October 2005) (Member); Officer/Scientific Societies (2004–2005)
- University of Adelaide; Australian National Health and Medical Research Council (NHMRC).; Ad Hoc Reviewer Promotion Committee (2004)
- University of Adelaide; Australian National Health and Medical Research Council (NHMRC).; Ad Hoc Reviewer Promotion Committee (2003)
- Biological Rhythms and Sleep Study Section; Study Section Member (2003–2004)
- IUPHAR Neuropharmacology Section; Secretary-Treasurer (2002–2006)
- ASPET Women in Pharmacology Committee (Member); Officer/Scientific Societies (2002–2005)
- Tumor Biology (2002)
- Society for Research In Biological Rhythms; Executive Advisory Committee (2002)
- Site Visit / Special Emphasis Panel, NINDS-2002/10 Council ZNS1 SRB-H (S2) (Member); Study Section Member (2002)
- University of Adelaide (Australia); Australian National Health and Medical Research Council (NHMRC).; Ad Hoc Reviewer Promotion Committee (2001)
- Officer/Scientific Societies - Division of Pharmacology Education of ASPET; Executive Board (2001–2005)
- The Sigma and RBI Handbook of Receptor Classification and Signal Transduction Handbook. Contributor to Melatonin Receptor Nomenclature and Signaling.; Workshop/Working Group Participant (2000–2015)
- British Journal of Pharmacology (BJP) Compendium – Contributor to Melatonin Receptor Nomenclature.; Workshop/Working Group Participant (2000–2015)
- Center for Scientific Review Advisory Committee to evaluate peer review within the Integrative, Functional and Cognitive Neuroscience Integrated Review Group (IFCN IRG). Center for Scientific Review (CSR), NIH.; Workshop/Working Group Participant (2000–2015)
- Workshop on “Circadian Rhythms in Human Health and Disorders,” National Institute of Environmental Health Sciences (NIEHS), September 14–15, 2006, Georgetown, Washington, DC.; Workshop/Working Group Participant (2000–2006)
- Neuroscience (2000)
- Bank of Reviewers of the National Agency of Scientific and Technological Evaluations, Medical Science, FONCYT, Buenos Aires, Argentina.; Ad Hoc Reviewer of Grants and Fellowships (2000)
- NSERC Award, Canada; Ad Hoc Reviewer of Grants and Fellowships (2000)
- PSC-CUNNY 32 Research Award, The City University of New York, NY.; Ad Hoc Reviewer of Grants and Fellowships (2000)
- Special Emphasis Panel - Integrative, Functional and Cognitive Neuroscience 3 (IFCN-3) (CSR/NIH); Study Section Member (2000–2003)
- Channel 2 Evening News, Interview with Dr. Breener; MEDIA INTERVIEWS AND ARTICLES (1999–present)
- Channel 5 Evening News, Interviewed by R. L. Ray for TV show on Sleep (Aired May 15–16, 1999); MEDIA INTERVIEWS AND ARTICLES (1999–present)
- Chicago Tribune, Interviewed and quoted on article on Sleep in adolescents (March 28, 1999); MEDIA INTERVIEWS AND ARTICLES (1999–present)
- Pharmacology and Toxicology (1999)
- Journal Neurological Sciences (1999)
- Pharmacological Reviews (1999)
- The University Texas, Health Science Center at San Antonio (TX); committee chair by Dr. Mifflin; Ad Hoc Reviewer Promotion Committee (1999)
- University of Aberdeen, King’s College (Scotland, UK); requested by Professor D. Houlihan (Dean); Ad Hoc Reviewer Promotion Committee (1999)
- Officer/Scientific Societies - ASPET Committee on Minorities Affairs Member (1999–2002); Chair (2002–2005); Past Chair (2005–2006); Member/Chair/Past Chair (1999–2006)
- Work Safety Magazine, Interview on Electric Magnetic Fields (EMF) Working Group Meeting; MEDIA INTERVIEWS AND ARTICLES (1998–present)
- Chicago Tribune, Interviewed and quoted on article on Electric Magnetic Fields (EMF); MEDIA INTERVIEWS AND ARTICLES (1998–present)
- Melatonin Club; President (1998–2006)
- Molecular Endocrinology (1998)
- EMF RAPID NIEHS Working Group Report (Member). “Health Effects from Exposure to Power-Line Frequency Electric and Magnetic Fields.” (The group was charged with preparing the EMF-RAPID final report for presentation to Congress). June 15–24, 1998, Minnesota.; Workshop/Working Group Participant (1998)
- EMF RAPID Science Review Symposium. “Melatonin” April 6-9, 1998, Phoenix, Arizona.; Workshop/Working Group Participant (1998–1988)
- Channel 2 Evening News, Interview with Dr. Breener; MEDIA INTERVIEWS AND ARTICLES (1997–present)
- Fundraising Subcommittee, Society for Neuroscience, Chicago, IL; Officer/Scientific Societies (1997–1998)
- Journal of Biological Rhythms (1997)
- Trends in Neuroscience (1997)
- Journal of Immunology (1997)
- Molecular and Cell Biochemistry (1997)
- Pharmacological Biochemistry and Behavior (1997)
- Journal of Clinical Investigation (1997)
- Bioorganic and Medicinal Chemistry (1997)
- Molecular Pharmacology (1997)
- Neuroendocrinology (1997)
- Massachusetts Institute of Technology (Cambridge, MA); committee chair Dr. E. Bizzi; Ad Hoc Reviewer Promotion Committee (1997)
- American Drugist Magazine, Interview with Laura Klepacki; MEDIA INTERVIEWS AND ARTICLES (1996–present)
- Men’s Journal Magazine, Interview; MEDIA INTERVIEWS AND ARTICLES (1996–present)
- Catecholamine Club: Councilor (1992-2011); President (1997–1998); President (2001-2002); Officer/Scientific Societies (1996–2011)
- Workshop on “Melatonin and Sleep.” NIA (NIH); Workshop/Working Group Participant (1996)
- Channel 2 News, Interview with Martha Lebau; MEDIA INTERVIEWS AND ARTICLES (1995–present)
- NU News/NU Actuality Services, Radio Interview with Chelsea & Mary Jane; MEDIA INTERVIEWS AND ARTICLES (1995–present)
- News Week Magazine, Phone Interview with Karen, Chicago Bureau; MEDIA INTERVIEWS AND ARTICLES (1995–present)
- Channel 2 Evening News, Interview with Dr. Breener; MEDIA INTERVIEWS AND ARTICLES (1995–present)
- Channel 5 Morning News, Interview with Wendy Telerico; MEDIA INTERVIEWS AND ARTICLES (1995–present)
- American Bar Association Journal, Phone Interview with Barbara Buchholz; MEDIA INTERVIEWS AND ARTICLES (1995–present)
- Radio France International, Interview in English and Spanish with Carol Pineau; MEDIA INTERVIEWS AND ARTICLES (1995–present)
- USA Today; MEDIA INTERVIEWS AND ARTICLES (1995–present)
- Endocrinology (1995)
- General and Comparative Endocrinology (1995)
- Air Force Office of Scientific Research; Ad Hoc Reviewer of Grants and Fellowships (1995)
- IUPHAR International Union of Pharmacology Subcommittee for Melatonin Receptor Nomenclature and Classification; Chair (1995–2015)
- Science (1994)
- Psychopharmacology (1994)
- Current Eye Research (1994)
- Montana State University, Bozeman, Montana; Ad Hoc Reviewer of Grants and Fellowships (1994)
- Instituto Venezolano Investigaciones Cientificas (Caracas, Venezuela); committee chair Dr. A. Soyano; Ad Hoc Reviewer Promotion Committee (1994)
- Investigative Ophthalmology & Visual Science (1993)
- Biological Signals (1993)
- Medical Research Council (MRC), London, UK; Ad Hoc Reviewer of Grants and Fellowships (1993)
- American Cancer Society, Atlanta, GA; Ad Hoc Reviewer of Grants and Fellowships (1993)
- National Institute of Mental Health (Bethesda, MA); committee chair Dr. J.M. Saavedra; Ad Hoc Reviewer Promotion Committee (1993)
- Local Organizing Committee, 3rd IUPHAR Satellite Meeting on “SEROTONIN”, July 30–August 3, 1994, Chicago, IL (Member); Officer/Scientific Societies (1993–1994)
- PANG, S.F., DUBOCOVICH, M.L. and BROWN, G.M.: “Biological Signals.” Issue on “Melatonin Receptors in Peripheral Tissues.” The Medical Scientific Publishers, Karger, Basel (1993)
- Journal of Medicinal Chemistry (1992)
- The Israel Science Foundation, Jerusalem, Israel; Ad Hoc Reviewer of Grants and Fellowships (1992)
- NIMH Neurochemistry and Neuropharmacology Review Committee (NIH); Study Section Member (1992–1996)
- Journal of Endocrinology (1991)
- American Journal of Physiology (1991)
- Naunyn Schmiedebergs’ Arch. of Pharmacology (1991)
- Pharmacology Communications. Harwood Academic Publishers, Switzerland; Associated Editor (1991–2004)
- USA Today; MEDIA INTERVIEWS AND ARTICLES (1990–present)
- Croatian Institute for Brain Research, Zagreb, Croatia; Scientific Advisory Board Member (1990–2005)
- ASPET Division of Neuropharmacology Executive Committee (Member); Officer/Scientific Societies (1990–1992)
- Molecular and Cellular Neurobiology (1990)
- Neuroscience Letters (1990)
- Proceedings National Academy of Science (1990)
- Journal of Pineal Research (1990)
- Allegheny Singer Research Institute, Pittsburgh, PA; Ad Hoc Reviewer of Grants and Fellowships (1990)
- Interneuron Pharmaceuticals Inc., Cambridge, Massachusetts; Scientific Advisory Board Member (1989–1990)
- Neuroendocrinology (1989)
- BRSG Grants for the University of Alaska, Fairbanks, Alaska; Ad Hoc Reviewer of Grants and Fellowships (1989)
- National Institute of Mental Health (Bethesda, MA); committee chair Dr. R.M. Cohen; Ad Hoc Reviewer Promotion Committee (1989)
- Various Insitutes Northwestern University Neuroscience Institute, Robert H. Lurie Cancer Center, The Asher Center for the Study & Treatment of Depressive Disorders, Center for Drug Discovery and Chemical Biology, Center for Sleep and Circadian Biology; Participant (1989–2008)
- Doctoral Fellowships in Biol. Science, Review Panel, Howard Hughes Medical Institute; Reviewer/Study Section Member (1989–1992)
- DUBOCOVICH, M.L.: “Molecular and Cellular Neurobiology” Issues on “Retina,” Vol. I and II, Plenum Publishing Corporation, NY; Special Issue Editor (1989–1991)
- European Journal of Pharmacology (1988)
- Grants-In-Aid Review Committee, American Heart Association, Chicago; Study Section Member (1988)
- Experimental Eye Research (1987)
- National Science Foundation; Ad Hoc Reviewer of Grants and Fellowships (1987)
- NIH Fogarty Fellowship Program; Ad Hoc Reviewer of Grants and Fellowships (1987)
- New York Academy of Science; Ad Hoc Reviewer of Symposium Proposals (1986)
- Neurochemistry International (1986–2022)
- Circulation Research (1986)
- Experientia (1986)
- Brain Research (1986)
- Alcohol and Drug Research (1986)
- Journal of Cardiovascular Pharmacology (1986)
- Chicago Chapter Society for Neuroscience Councilor (1985–1989), Secretary Treasurer (1989–1990), Treasurer (1990–1993). President Elect (1993–1994), President (1994–1995), Past President (1995–1996).; Officer/Scientific Societies (1985–1996)
- Journal of Neurochemistry (1985)
- Biological Psychiatry (1985)
- Neuropharmacology (1984)
- Therapeutics (1983)
- Life Science (1983)
- Journal of Pharmacology Experimental